Drug Transporter (DT) Information

General Information of DT
DT ID DTD0005
Gene Name SLC22A7
Protein Name Organic anion transporter 2
Gene ID
10864
UniProt ID
Q9Y694
TCDB ID
2.A.1.19.25
3D Structure

Modelled DT Structure

Method: multi-sequence alignment based machine learning

Detail: Structure Info

Synonyms NLT; Novel liver transporter; OAT2; SLC22A7; Solute carrier family 22 member 7; hOAT11; hOAT2
DT Family Major Facilitator Superfamily (MFS)
Organic Cation Transporter (OCT) Family
Tissue Specificity Highly expressed in the liver and, to a lesser extent, in the kidney
Function This sodium-independent transporter mediates the transport of multispecific organic anion. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Disease(s) Chronic obstructive pulmonary disease [ICD-11:CA22]
Edema associated with congestive heart failure [ICD-11:BD10]
Human immunodeficiency virus infection [ICD-11:1C62.Z]
Hyperuricaemia [ICD-11:5C55.Y]
Leukemia [ICD-11:2A60-2B33]
Pain [ICD-11:MG30-MG7Z]
Peptic ulcer [ICD-11:DA61]
Herpes simplex virus infection [ICD-11:1F00]
Chlamydia infections [ICD-11:1C2Z]
Endogenous Substrate(s) Organic anions; 2'-Deoxyguanosine
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 4.0)

(α) Tissue Distribution Level of Organic anion transporter 2
Tissue Distribution Level (TD)

(β) Cell Distribution Level of Organic anion transporter 2
Cell Distribution Level (CD)

(γ) Organelle Distribution Level of Organic anion transporter 2
Organelle Distribution Level (Subc)

Regulatory Variability Data of This DT

(α) Microbiota Influence of Organic anion transporter 2
Microbiota Influence (MBI)

(β) Post-translational Modification of Organic anion transporter 2
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of Organic anion transporter 2
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of Organic anion transporter 2
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of Organic anion transporter 2
Exogenous Modulation (EGM)

Structural Variability Data of This DT

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

General Variability Data of This DT

(α) Genetic Polymorphisms of Organic anion transporter 2
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of Organic anion transporter 2
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:         15 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Acyclovir
 Approved Drug Info Shingles 1.00E+91 [1]
Allopurinol
 Approved Drug Info Hyperuricaemia 5C55.Y [2]
Aspirin
 Approved Drug Info Pain MG30-MG7Z [3]
Bumetanide
 Approved Drug Info Edema associated with congestive heart failure BD10 [4]
Dinoprostone
 Approved Drug Info Medical abortion JA00.1 [5]
Entecavir
 Approved Drug Info Chronic hepatitis B infection 1E51.0 [6]
Erythromycin
 Approved Drug Info Pelvic inflammatory disease GA05 [7]
Fluorouracil
 Approved Drug Info Stomach cancer 2B72 [4]
Methotrexate
 Approved Drug Info Leukemia 2A60-2B33 [8]
Paclitaxel
 Approved Drug Info Breast cancer 2C60-2C6Z [4]
Penciclovir
 Approved Drug Info Herpes simplex virus infection 1F00 [9]
Ranitidine
 Approved Drug Info Peptic ulcer DA61 [10]
Tetracycline
 Approved Drug Info Gram-positive & negative bacteria infections 1A00-1H0Z [11]
Theophylline
 Approved Drug Info Chronic obstructive pulmonary disease CA22 [7]
Zidovudine
 Approved Drug Info Human immunodeficiency virus infection 1C62.Z [12]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:           1 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Prostaglandin f2Alpha
 Preclinical Drug Info Solid tumours 2D4Z [13]

Endogenous Metabolites (EMs) Handled by This DT

 Endogenous Metabolites (EMs)

 Click to Show/Hide the Full List of EMs:           1 EMs in Total
EM Name PubChem CID Detail Experimental Material Ref
Amino acid unspecific N.A. EM Info Unclear experiment used for identifying this EM [14]

Drug-DT Affinity Assessed by Cell Line

 Approved Drug

 Click to Show/Hide the Full List of Drug:         63 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Bumetanide Approved Drug Info Oocytes-OAT2 Km =7.52 microM [4]
Bumetanide Approved Drug Info Oocytes-OAT2 Km =7.52 microM [4]
Bumetanide Approved Drug Info Oocytes-OAT2 Km =7.52 microM [4]
Bumetanide Approved Drug Info Oocytes-OAT2 Km =7.52 microM [4]
Bumetanide Approved Drug Info Oocytes-OAT2 Km =7.52 microM [4]
Dinoprostone Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =0.713 microM [5]
Dinoprostone Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =0.713 microM [5]
Dinoprostone Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =0.713 microM [5]
Dinoprostone Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =0.713 microM [5]
Dinoprostone Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =0.713 microM [5]
Dinoprostone Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =0.713 microM [5]
Dinoprostone Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =0.713 microM [5]
Dinoprostone Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =0.713 microM [5]
Dinoprostone Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =0.713 microM [5]
Dinoprostone Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =0.713 microM [5]
Dinoprostone Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =0.713 microM [5]
Dinoprostone Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =0.713 microM [5]
Dinoprostone Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =0.713 microM [5]
Dinoprostone Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =0.713 microM [5]
Dinoprostone Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =0.713 microM [5]
Dinoprostone Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =0.713 microM [5]
Dinoprostone Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =0.713 microM [5]
Dinoprostone Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =0.713 microM [5]
Dinoprostone Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =0.713 microM [5]
Dinoprostone Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =0.713 microM [5]
Erythromycin Approved Drug Info Oocytes-OAT2 Km =18.5 microM [7]
Erythromycin Approved Drug Info Oocytes-OAT2 Km =18.5 microM [7]
Erythromycin Approved Drug Info Oocytes-OAT2 Km =18.5 microM [7]
Erythromycin Approved Drug Info Oocytes-OAT2 Km =18.5 microM [7]
Erythromycin Approved Drug Info Oocytes-OAT2 Km =18.5 microM [7]
Fluorouracil Approved Drug Info Oocytes-OAT2 Km =0.0538 microM [4]
Fluorouracil Approved Drug Info Oocytes-OAT2 Km =0.0538 microM [4]
Fluorouracil Approved Drug Info Oocytes-OAT2 Km =0.0538 microM [4]
Fluorouracil Approved Drug Info Oocytes-OAT2 Km =0.0538 microM [4]
Fluorouracil Approved Drug Info Oocytes-OAT2 Km =0.0538 microM [4]
Fluorouracil Approved Drug Info Oocytes-OAT2 Km =0.0538 microM [4]
Fluorouracil Approved Drug Info Oocytes-OAT2 Km =0.0538 microM [4]
Fluorouracil Approved Drug Info Oocytes-OAT2 Km =0.0538 microM [4]
Paclitaxel Approved Drug Info Oocytes-OAT2 Km =0.1428 microM [4]
Paclitaxel Approved Drug Info Oocytes-OAT2 Km =0.1428 microM [4]
Paclitaxel Approved Drug Info Oocytes-OAT2 Km =0.1428 microM [4]
Paclitaxel Approved Drug Info Oocytes-OAT2 Km =0.1428 microM [4]
Paclitaxel Approved Drug Info Oocytes-OAT2 Km =0.1428 microM [4]
Paclitaxel Approved Drug Info Oocytes-OAT2 Km =0.1428 microM [4]
Paclitaxel Approved Drug Info Oocytes-OAT2 Km =0.1428 microM [4]
Paclitaxel Approved Drug Info Oocytes-OAT2 Km =0.1428 microM [4]
Paclitaxel Approved Drug Info Oocytes-OAT2 Km =0.1428 microM [4]
Paclitaxel Approved Drug Info Oocytes-OAT2 Km =0.1428 microM [4]
Paclitaxel Approved Drug Info Oocytes-OAT2 Km =0.1428 microM [4]
Tetracycline Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =439.9 microM [11]
Tetracycline Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =439.9 microM [11]
Tetracycline Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =439.9 microM [11]
Tetracycline Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =439.9 microM [11]
Tetracycline Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =439.9 microM [11]
Theophylline Approved Drug Info Oocytes-OAT2 Km =12.6 microM [7]
Zidovudine Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =26.8 microM [12]
Zidovudine Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =26.8 microM [12]
Zidovudine Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =26.8 microM [12]
Zidovudine Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =26.8 microM [12]
Zidovudine Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =26.8 microM [12]
Zidovudine Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =26.8 microM [12]
Zidovudine Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =26.8 microM [12]
Zidovudine Approved Drug Info Proximal tubule (S2) cells-OAT2 Km =26.8 microM [12]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:           9 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Prostaglandin f2Alpha Preclinical Drug Info Proximal tubule (S2) cells-OAT2 Km =0.425 microM [13]
Prostaglandin f2Alpha Preclinical Drug Info Proximal tubule (S2) cells-OAT2 Km =0.425 microM [13]
Prostaglandin f2Alpha Preclinical Drug Info Proximal tubule (S2) cells-OAT2 Km =0.425 microM [13]
Prostaglandin f2Alpha Preclinical Drug Info Proximal tubule (S2) cells-OAT2 Km =0.425 microM [13]
Prostaglandin f2Alpha Preclinical Drug Info Proximal tubule (S2) cells-OAT2 Km =0.425 microM [13]
Prostaglandin f2Alpha Preclinical Drug Info Proximal tubule (S2) cells-OAT2 Km =0.425 microM [13]
Prostaglandin f2Alpha Preclinical Drug Info Proximal tubule (S2) cells-OAT2 Km =0.425 microM [13]
Prostaglandin f2Alpha Preclinical Drug Info Proximal tubule (S2) cells-OAT2 Km =0.425 microM [13]
Prostaglandin f2Alpha Preclinical Drug Info Proximal tubule (S2) cells-OAT2 Km =0.425 microM [13]
References
1 Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol Pharmacol. 2008 Apr;73(4):1151-8.
2 Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. Mol Pharmacol. 2002 Jul;62(1):7-14.
3 Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82.
4 Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
5 Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
6 Human organic anion transporter 2 is an entecavir, but not tenofovir, transporter. Drug Metab Pharmacokinet. 2017 Feb;32(1):116-119.
7 Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22.
8 Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol. 2003;146:95-158.
9 In vitro studies with two human organic anion transporters: OAT2 and OAT7. Xenobiotica. 2018 Oct;48(10):1037-1049.
10 A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
11 Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.
12 Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
13 Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther. 2002 Jun;301(3):797-802.
14 Genetic Regulation of Liver Metabolites and Transcripts Linking to Biochemical-Clinical Parameters. Front Genet. 2019 Apr 17;10:348.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.